Anthoney, D Alan <br/><br/>
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.  [electronic resource] 

 -  BMC cancer  Nov 2012 
 - 536 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-12-536  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aldehyde Oxidase--genetics<br/>Area Under Curve<br/>Cytochrome P-450 CYP2D6--genetics<br/>DNA Damage<br/>Dipeptides--adverse effects<br/>Dose-Response Relationship, Drug<br/>Female<br/>Glucuronosyltransferase--genetics<br/>Heterocyclic Compounds, 4 or More Rings--adverse effects<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Molecular Structure<br/>Neoplasms--drug therapy<br/>Pharmacogenetics--methods<br/>Polymorphism, Genetic<br/>Prodrugs--adverse effects<br/>Thrombocytopenia--chemically induced<br/>Topoisomerase I Inhibitors--adverse effects<br/>Treatment Outcome